China Cord Blood Corporation announced that Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (limited partnership) (Nanjing Ying Peng), via its subsidiary, has become a major shareholder of the company. Following the entry of Nanjing Ying Peng, Mr. Ping Xu was appointed as a director of the Board of Directors of the company. Mr. Xu is a senior vice president of Sanpower Group Co. Ltd. and the authorized representative of the executive partner of Nanjing Ying Peng. Mr. Xu possesses extensive knowledge and experience in cross-border M&A and project financing. Mr. Xu also spearheaded multiple merger and acquisition initiatives both inside and outside of the People's Republic of China. Simultaneously, the company announced that Mr. Yuen Kam has resigned from his positions as Chairman and director of the Board and as Chairman and member of the Nominating and Corporate Governance Committee (the Nominating Committee) of the Company. His resignation was accepted by the Board and is effective as of January 31, 2018. Following Mr. Kam's resignation, Ms. Ting Zheng, Chief Executive Officer of the company, was appointed as the Chairperson of the Board and the Chairperson of the Nominating Committee. Mr. Mark Chen, one of the company's existing independent non-executive directors also joined as a new member to the Nominating Committee.